PURPOSE: This study evaluated the clinical factors associated with outcomes of head and neck @entity4153 (SCNEC-HN). MATERIALS AND METHODS: A retrospective review of clinical data was performed for 11 @entity1 with SCNEC-HN treated at the Hamamatsu University Hospital (Hamamatsu, Japan). Clinical features, treatment methods, and outcomes were evaluated. The main outcome measurements were disease stage, @entity1 age, primary @entity5 site, treatment procedures, and estimated survival rates. Survival rates were calculated using the Kaplan-Meier method. RESULTS: @entity1 were followed for a mean of 40.0  months (range, 8 to 191  months). The 1-, 2-, and 5-year overall survival rates were 52.0, 20.8, and 10.4%, respectively. Rates did not differ significantly between the N2 and N0/1 groups, although the latter had a slightly better prognosis (P  = .08). CONCLUSION: Chemoradiotherapy was a reasonable treatment for @entity1 with SCNEC-HN. Those with N0/1 or maxillary sinus SCNEC-HN had a better prognosis than those with N2 disease or @entity5 at other sites, respectively. However, more aggressive treatment might not be warranted even for @entity1 with limited disease. The outcomes continue to be suboptimal, and more effective therapies are needed because most @entity1 had local or distant failure.

XXXX Arising in the Head and Neck Region.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers'] @entity4153 :: ('MESH:D018288', 'Disease') :: ['small cell neuroendocrine carcinoma']
@entity4153 :: (MESH:D018288,Disease) :: ['Small Cell Neuroendocrine Carcinomas']
